Skip to main content

Caligan Partners LP's Form 4 filing

Standard Biotools Inc. (LAB) · filed Jun 15, 2022

Accession no.
0000902664-22-003296
Filed
Jun 15, 2022, 9:06 AM ET
Trade date
Jun 13, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 1 non-derivative transaction. Open-market purchases total $170.0K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Caligan Partners LPCIK 000172749210% Owner, Other: See Remarks
Johnson David EdwardCIK 000178555710% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 13, 2022Common Stock, $0.001 par value per share ("Common Stock")PPurchaseAcquired+100,000$1.70F1,F3+$170,00010,523,188Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Price is the volume weighted average price of all trades by Caligan Partners LP ("Caligan") and David Johnson (together with Caligan, the "Reporting Persons") on the transaction date for prices ranging from $1.64 to $1.75.

Referenced by the price of 1 transaction in Table I.

F3

The Reporting Persons hereby undertake to provide upon request of the staff of the Securities and Exchange Commission full information regarding the number of shares traded at each separate price.

Referenced by the price of 1 transaction in Table I.

Remarks

The Reporting Persons disclaim beneficial ownership in the securities reported on this Form 4 except to the extent of his or its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that any of the Reporting Persons are the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Read the full filing on SEC EDGAR (opens in a new tab)